{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:58:16Z","timestamp":1794895096073,"version":"4.9.1"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SB4519N"],"award-info":[{"award-number":["1SB4519N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0F8316N"],"award-info":[{"award-number":["G0F8316N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["T001018N"],"award-info":[{"award-number":["T001018N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI150349"],"award-info":[{"award-number":["K24AI150349"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Rifampicin resistant tuberculosis remains a global health problem with almost half a million new cases annually. In high-income countries patients empirically start a standardized treatment regimen, followed by an individualized regimen guided by drug susceptibility test (DST) results. In most settings, DST information is not available or is limited to isoniazid and fluoroquinolones. Whole genome sequencing could more accurately guide individualized treatment as the full drug resistance profile is obtained with a single test. Whole genome sequencing has not reached its full potential for patient care, in part due to the complexity of translating a resistance profile into the most effective individualized regimen.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We developed a treatment recommender clinical decision support system (CDSS) and an accompanying web application for user-friendly recommendation of the optimal individualized treatment regimen to a clinician.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Following expert stakeholder meetings and literature review, nine drug features and 14 treatment regimen features were identified and quantified. Using machine learning, a model was developed to predict the optimal treatment regimen based on a training set of 3895 treatment regimen-expert feedback pairs. The acceptability of the treatment recommender CDSS was assessed as part of a clinical trial and in a routine care setting. Within the clinical trial setting, all patients received the CDSS recommended treatment. In 8 of 20 cases, the initial recommendation was recomputed because of stock out, clinical contra-indication or toxicity. In routine care setting, physicians rejected the treatment recommendation in 7 out of 15 cases because it deviated from the national TB treatment guidelines. A survey indicated that the treatment recommender CDSS is easy to use and useful in clinical practice but requires digital infrastructure support and training.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our findings suggest that global implementation of the novel treatment recommender CDSS holds the potential to improve treatment outcomes of patients with RR-TB, especially those with \u2018difficult-to-treat\u2019 forms of RR-TB.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0306101","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T18:15:56Z","timestamp":1725646556000},"page":"e0306101","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-5852","authenticated-orcid":true,"given":"Lennert","family":"Verboven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7245-527X","authenticated-orcid":true,"given":"Steven","family":"Callens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7845-4972","authenticated-orcid":true,"given":"John","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Potgieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1063-4659","authenticated-orcid":true,"given":"Ruben","family":"Cartuyvels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SMARTT team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Laukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Van Rie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"pone.0306101.ref001","author":"World Health Organization (WHO)","year":"2022","journal-title":"Global Tuberculosis Report 2022"},{"key":"pone.0306101.ref002","author":"World Health Organization (WHO),","year":"2019","journal-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment"},{"key":"pone.0306101.ref003","author":"World Health Organization (WHO),","year":"2022","journal-title":"Rapid communication: key changes to the treatment of drug-resistant tuberculosis"},{"issue":"2","key":"pone.0306101.ref004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5588\/ijtld.20.0598","article-title":"Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.","volume":"25","author":"E. De Vos","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0306101.ref005","author":"World Health Organization (WHO),","year":"2021","journal-title":"WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update"},{"issue":"3","key":"pone.0306101.ref006","article-title":"Xpert MTB\/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum","volume":"59","author":"Y. Cao","year":"2021","journal-title":"J Clin Microbiol"},{"key":"pone.0306101.ref007","author":"World Health Organization","year":"2018","journal-title":"Technical guide on next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex"},{"issue":"6","key":"pone.0306101.ref008","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cmi.2017.10.001","article-title":"Turnaround time of whole genome sequencing for mycobacterial identification and drug susceptibility testing in routine practice","volume":"24","author":"I.D. Olaru","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"pone.0306101.ref009","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1128\/JCM.00298-17","article-title":"Comprehensive Whole-Genome Sequencing and Reporting of Drug Resistance Profiles on Clinical Cases of Mycobacterium tuberculosis in New York State","volume":"55","author":"J. Shea","year":"2017","journal-title":"J Clin Microbiol"},{"key":"pone.0306101.ref010","article-title":"Whole genome sequencing (WGS) is now being used to identify different strains of tuberculosis (TB), announced Public Health England today","author":"Public Health England","year":"2017"},{"issue":"3","key":"pone.0306101.ref011","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/PAT.0000000000000235","article-title":"Whole genome sequencing in clinical and public health microbiology","volume":"47","author":"J.C. Kwong","year":"2015","journal-title":"Pathology"},{"issue":"8","key":"pone.0306101.ref012","doi-asserted-by":"crossref","first-page":"e1002824","DOI":"10.1371\/journal.ppat.1002824","article-title":"Routine use of microbial whole genome sequencing in diagnostic and public health microbiology","volume":"8","author":"C.U. Koser","year":"2012","journal-title":"PLoS Pathog"},{"issue":"4","key":"pone.0306101.ref013","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmi.2017.11.001","article-title":"Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology","volume":"24","author":"J.W.A. Rossen","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"pone.0306101.ref014","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12911-022-01790-0","article-title":"A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis.","volume":"22","author":"L. Verboven","year":"2022","journal-title":"BMC Med Inform Decis Mak"},{"key":"pone.0306101.ref015","author":"World Health Organization (WHO)","year":"2017","journal-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) Annex 6"},{"key":"pone.0306101.ref016","author":"World Health Organization (WHO),","year":"2019","journal-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment Annex 2."},{"key":"pone.0306101.ref017","article-title":"Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children","author":"The Department of Health of South Africa","year":"2018"},{"key":"pone.0306101.ref018","author":"Stop TB Partnership","year":"2016","journal-title":"Global Drug Facility Product catalogue"},{"key":"pone.0306101.ref019","author":"World Health Organization (WHO),","year":"2021","journal-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance"},{"issue":"null","key":"pone.0306101.ref020","first-page":"2825","article-title":"Scikit-learn: Machine Learning in Python.","volume":"12","author":"F. Pedregosa","year":"2011","journal-title":"J. Mach. Learn. Res."},{"key":"pone.0306101.ref021","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"P.A. Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"1","key":"pone.0306101.ref022","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1186\/s13063-022-06793-w","article-title":"Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial.","volume":"23","author":"A. Van Rie","year":"2022","journal-title":"Trials"},{"issue":"1","key":"pone.0306101.ref023","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/tmj.2011.0066","article-title":"Using a modified technology acceptance model to evaluate healthcare professionals\u2019 adoption of a new telemonitoring system.","volume":"18","author":"M.P. Gagnon","year":"2012","journal-title":"Telemed J E Health"},{"issue":"18","key":"pone.0306101.ref024","doi-asserted-by":"crossref","first-page":"12300","DOI":"10.1074\/jbc.M113.529164","article-title":"Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding","volume":"289","author":"A. Mustaev","year":"2014","journal-title":"J Biol Chem"},{"issue":"3","key":"pone.0306101.ref025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00803-2016","article-title":"An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis","volume":"49","author":"M.L. Bastos","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"pone.0306101.ref026","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/0091270008330984","article-title":"Electrocardiographic QTc changes due to moxifloxacin infusion","volume":"49","author":"M. Malik","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"pone.0306101.ref027","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/14787210.2014.870884","article-title":"The early bactericidal activity of antituberculosis drugs","volume":"12","author":"A.H. Diacon","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"pone.0306101.ref028","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1164\/rccm.201212-2328OC","article-title":"Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis","volume":"188","author":"Z. Ahmad","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"pone.0306101.ref029","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"B. Prideaux","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"pone.0306101.ref030","article-title":"Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis","volume":"61","author":"S.Y. Li","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0306101.ref031","doi-asserted-by":"crossref","DOI":"10.1128\/ecosalplus.esp-0017-2019","article-title":"Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules","volume":"9","author":"H. Mosaei","year":"2020","journal-title":"EcoSal Plus"},{"issue":"5","key":"pone.0306101.ref032","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0962-8479(94)90079-5","article-title":"Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group","volume":"75","author":"L.J. Gonzalez-Montaner","year":"1994","journal-title":"Tuber Lung Dis"},{"issue":"6","key":"pone.0306101.ref033","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/32.6.867","article-title":"The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment","volume":"32","author":"F.A. Sirgel","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pone.0306101.ref034","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0041-3879(85)90040-6","article-title":"The action of antituberculosis drugs in short-course chemotherapy","volume":"66","author":"D.A. Mitchison","year":"1985","journal-title":"Tubercle"},{"issue":"4","key":"pone.0306101.ref035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jyp.2013.12.002","article-title":"Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis","volume":"5","author":"M. Lakshmanan","year":"2013","journal-title":"J Young Pharm"},{"issue":"8","key":"pone.0306101.ref036","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.01204-07","article-title":"Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis","volume":"52","author":"R. Rustomjee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"2 Pt 1","key":"pone.0306101.ref037","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(95)90134-5","article-title":"Clofazimine: a review of its medical uses and mechanisms of action","volume":"32","author":"J.L. Arbiser","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"pone.0306101.ref038","article-title":"Clofazimine does not lead to significant QT interval prolongation: a multicentre study","volume":"52","author":"S.M.H. Zweijpfenning","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"pone.0306101.ref039","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"R.V. Swanson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0306101.ref040","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"S.M.R. Hashemian","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"pone.0306101.ref041","first-page":"CD012836","article-title":"Linezolid for drug-resistant pulmonary tuberculosis","volume":"3","author":"B. Singh","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"Pt 5","key":"pone.0306101.ref042","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1099\/mic.0.27804-0","article-title":"Ethambutol, a cell wall inhibitor of Mycobacterium tuberculosis, elicits L-glutamate efflux of Corynebacterium glutamicum","volume":"151","author":"E. Radmacher","year":"2005","journal-title":"Microbiology (Reading),"},{"issue":"2","key":"pone.0306101.ref043","first-page":"155","article-title":"Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis","volume":"86","author":"F.J. Botha","year":"1996","journal-title":"S Afr Med J"},{"issue":"5","key":"pone.0306101.ref044","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Y. Zhang","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"pone.0306101.ref045","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"A. Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"pone.0306101.ref046","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1128\/AAC.35.6.1035","article-title":"Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum","volume":"35","author":"A. Quemard","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"pone.0306101.ref047","article-title":"Ethionamide Preconditioning Enhances the Proliferation and Migration of Human Wharton\u2019s Jelly-Derived Mesenchymal Stem Cells.","volume":"21","author":"N.H. Lee","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"42","key":"pone.0306101.ref048","doi-asserted-by":"crossref","first-page":"30414","DOI":"10.1074\/jbc.M704286200","article-title":"Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem","volume":"282","author":"J.L. Mainardi","year":"2007","journal-title":"J Biol Chem"},{"issue":"7","key":"pone.0306101.ref049","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1128\/AAC.49.7.2816-2821.2005","article-title":"Imipenem for treatment of tuberculosis in mice and humans","volume":"49","author":"H.F. Chambers","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5918","key":"pone.0306101.ref050","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"J.E. Hugonnet","year":"2009","journal-title":"Science"},{"issue":"9","key":"pone.0306101.ref051","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2013315118","article-title":"Real-time measurements of aminoglycoside effects on protein synthesis in live cells","volume":"118","author":"J. Aguirre Rivera","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pone.0306101.ref052","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/48.6.869","article-title":"The activity of low-clearance liposomal amikacin in experimental murine tuberculosis","volume":"48","author":"J. Dhillon","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"pone.0306101.ref053","author":"National Center for Biotechnology Information","year":"2022","journal-title":"PubChem Compound Summary for CID 6234, Cycloserine."},{"issue":"10","key":"pone.0306101.ref054","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.5588\/ijtld.12.0863","article-title":"Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis","volume":"17","author":"T.J. Hwang","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"32","key":"pone.0306101.ref055","doi-asserted-by":"crossref","first-page":"23447","DOI":"10.1074\/jbc.M113.475798","article-title":"para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis","volume":"288","author":"J. Zheng","year":"2013","journal-title":"J Biol Chem"},{"issue":"3","key":"pone.0306101.ref056","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/14787210.2015.1011127","article-title":"Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.","volume":"13","author":"G. Sotgiu","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"pone.0306101.ref057","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00537-2018","article-title":"QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.","volume":"52","author":"L. Guglielmetti","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"pone.0306101.ref058","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/jac\/dkm291","article-title":"Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis","volume":"60","author":"O.Y. Saliu","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pone.0306101.ref059","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"A. Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"pone.0306101.ref060","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.00898-06","article-title":"Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis","volume":"51","author":"M. Ibrahim","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0306101.ref061","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/AAC.01691-15","article-title":"Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis","volume":"60","author":"R. Tasneen","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0306101.ref062","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dkx004","article-title":"Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB","volume":"72","author":"A. Naidoo","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"pone.0306101.ref063","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug","volume":"70","author":"E.M. Svensson","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"pone.0306101.ref064","article-title":"WHO consolidated guidelines on tuberculosis.","author":"World Health Organization (WHO),","year":"2022","journal-title":"Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update."},{"issue":"2","key":"pone.0306101.ref065","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/QAI.0000000000002118","article-title":"Development and Validation of HIV-ASSIST, an Online, Educational, Clinical Decision Support Tool to Guide Patient-Centered ARV Regimen Selection.","volume":"82","author":"M.V. Maddali","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0306101.ref066","author":"Medscape Drug Reference Database","year":"2022","journal-title":"Drug Interaction Checker."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T18:16:38Z","timestamp":1725646598000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306101"}},"subtitle":[],"editor":[{"given":"Meredith Blair","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0306101","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0306101.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0306101.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0306101.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0306101.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0306101.t003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0306101.t004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0306101.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0306101.s002","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}